目的 探讨采用槐耳颗粒联合替吉奥治疗晚期结直肠癌患者的临床效果。方法 选取天津医科大学肿瘤医院于2015年8月-2016年8月收治的晚期结直肠癌患者111例，随机分成对照组（55例）和治疗组（56例）。对照组患者口服替吉奥胶囊，患者体表面积<1.25 m²，40 mg/次，若体表面积1.25~1.50 m²，50 mg/次，若体表面积>1.5 m²，60 mg/次，早晚各1次，连续服用14 d，然后停药7 d为1个疗程。治疗组患者在对照组的基础上口服槐耳颗粒，1袋/次，3次/d，21 d为1个疗程。两组患者均连续治疗3个疗程。评价两组患者临床疗效，同时比较治疗前后两组患者KPS和QOL评分以及血清标志物和免疫指标水平变化。结果 治疗后，对照组患者客观缓解率和疾病控制率分别为34.54%、65.45%，均分别低于治疗组的57.14%、89.29%，两组比较差异均具有统计学意义（P<0.05）。治疗后，两组患者KPS和QOL评分均显著升高（P<0.05）；且治疗组患者KPS和QOL评分明显高于对照组患者（P<0.05）。治疗后，两组患者癌胚抗原（CEA）、IL-9以及转化生长因子-β（TGF-β）血清水平均显著降低（P<0.05）；且治疗组患者各血清标志物水平均明显低于对照组（P<0.05）。治疗后，两组患者IgA、IgM和IgG血清水平均显著升高（P<0.05）；且治疗组患者免疫指标均明显高于对照组（P<0.05）。结论 槐耳颗粒联合替吉奥胶囊治疗晚期结直肠癌疗效显著，能够改善患者血清标志物和免疫指标水平，且安全性高，具有一定的临床推广应用价值。

Objective To explore the clinical effect of Huaier Granules combined with tegafur, gimeracil and oteracil potassium in treatment of advanced colorectal cancer. Methods Patients (111 cases) with advanced colorectal cancer in Tianjin Medical University Cancer Hospital from August 2015 to August 2016 were divided into control (55 cases) and treatment (56 cases) groups. Patients in the control group were po administered with Tegafur Gimeracil Oteracil Potassium Capsules, 40 mg/time for the patients of body surface area less than 1.25 m², and 50 mg/time for the patients of body surface area less than 1.25-1.50 m², and 60 mg/time for the patients of body surface area more than 1.5 m², twice daily, and one course of treatment was 14 d of treatment and 7 d of withdrawal. Patients in the treatment group were po administered with Huaier Granules on the basis of the control group, 1 bag/time, three times daily, one course of treatment was 21 d. Patients in two groups were treated for 3 courses of treatment. After treatment, the clinical efficacy was evaluated, and the change of KPS and QOL scores, serum markers and immune indexes in two groups before and after treatment was compared. Results After treatment, objective remission rate and disease control rate in the control group were 34.54% and 65.45%, which were significantly lower than 57.14% and 89.29% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the KPS and QOL scores in two groups were significantly increased (P<0.05). And the KPS and QOL scores in the treatment group were obviously higher than that in the control group (P<0.05). After treatment, the serum CEA, IL-9 and TGF-β levels in two groups were significantly decreased (P<0.05). And the serum markers levels in the treatment group were obviously lower than those in the control group (P<0.05). After treatment, the serum IgA, IgM and IgG levels in two groups were significantly increased (P<0.05). And the improvement of these immune indexes in the treatment group was obviously better than that in the control group (P<0.05). Conclusion Huaier Granules combined with tegafur, gimeracil and oteracil potassium has significant effect in treatment of advanced colorectal cancer significantly, can significantly improve serum markers and immune indicators with high security, which has a certain clinical application value.